CN112512999B - 新型联苯衍生物化合物及其用途 - Google Patents
新型联苯衍生物化合物及其用途 Download PDFInfo
- Publication number
- CN112512999B CN112512999B CN201980050493.0A CN201980050493A CN112512999B CN 112512999 B CN112512999 B CN 112512999B CN 201980050493 A CN201980050493 A CN 201980050493A CN 112512999 B CN112512999 B CN 112512999B
- Authority
- CN
- China
- Prior art keywords
- cancer
- derivative compound
- biphenyl derivative
- acid
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 biphenyl derivative compound Chemical class 0.000 title claims abstract description 56
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 79
- 201000011510 cancer Diseases 0.000 claims abstract description 76
- 206010027476 Metastases Diseases 0.000 claims abstract description 35
- 230000009401 metastasis Effects 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 230000002401 inhibitory effect Effects 0.000 claims description 20
- 239000004480 active ingredient Substances 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- 206010043515 Throat cancer Diseases 0.000 claims description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 201000011165 anus cancer Diseases 0.000 claims description 2
- 201000006491 bone marrow cancer Diseases 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 201000011061 large intestine cancer Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000006134 tongue cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 201000004962 larynx cancer Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 36
- 230000000694 effects Effects 0.000 abstract description 28
- 238000011282 treatment Methods 0.000 abstract description 21
- 108700023477 Nucleoside diphosphate kinases Proteins 0.000 abstract description 20
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 230000005907 cancer growth Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 35
- 238000000034 method Methods 0.000 description 30
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 239000003814 drug Substances 0.000 description 14
- 235000010290 biphenyl Nutrition 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000012981 Hank's balanced salt solution Substances 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
- 101100293798 Mus musculus Nme1 gene Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 5
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- BMQDAIUNAGXSKR-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid Chemical class CC(C)(O)C(C)(C)OB(O)O BMQDAIUNAGXSKR-UHFFFAOYSA-N 0.000 description 3
- NDOPHXWIAZIXPR-UHFFFAOYSA-N 2-bromobenzaldehyde Chemical compound BrC1=CC=CC=C1C=O NDOPHXWIAZIXPR-UHFFFAOYSA-N 0.000 description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000013901 Nucleoside diphosphate kinase Human genes 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 101710100179 UMP-CMP kinase Proteins 0.000 description 3
- 101710119674 UMP-CMP kinase 2, mitochondrial Proteins 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- CMSYDJVRTHCWFP-UHFFFAOYSA-N triphenylphosphane;hydrobromide Chemical class Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CMSYDJVRTHCWFP-UHFFFAOYSA-N 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- RCVDPBFUMYUKPB-UHFFFAOYSA-N (3,4-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1OC RCVDPBFUMYUKPB-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000002257 antimetastatic agent Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229960001867 guaiacol Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UBPDKIDWEADHPP-UHFFFAOYSA-N 2-iodoaniline Chemical compound NC1=CC=CC=C1I UBPDKIDWEADHPP-UHFFFAOYSA-N 0.000 description 1
- CJNZAXGUTKBIHP-UHFFFAOYSA-N 2-iodobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- LGDHZCLREKIGKJ-UHFFFAOYSA-N 3,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C=C1OC LGDHZCLREKIGKJ-UHFFFAOYSA-N 0.000 description 1
- DAUAQNGYDSHRET-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1OC DAUAQNGYDSHRET-UHFFFAOYSA-N 0.000 description 1
- 231100000582 ATP assay Toxicity 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical class OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000007807 Matrigel invasion assay Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 101150058540 RAC1 gene Proteins 0.000 description 1
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- GPVDHNVGGIAOQT-UHFFFAOYSA-N Veratric acid Natural products COC1=CC=C(C(O)=O)C(OC)=C1 GPVDHNVGGIAOQT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UHOVQNZJYSORNB-MZWXYZOWSA-N benzene-d6 Chemical compound [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H] UHOVQNZJYSORNB-MZWXYZOWSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OGBVRMYSNSKIEF-UHFFFAOYSA-L benzyl-dioxido-oxo-$l^{5}-phosphane Chemical compound [O-]P([O-])(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-L 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- ZDDZKHMZUVWNLR-UHFFFAOYSA-N n-(2-iodophenyl)-3,4-dimethoxybenzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=CC=CC=C1I ZDDZKHMZUVWNLR-UHFFFAOYSA-N 0.000 description 1
- IMDBISGKWOKHDY-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-2-iodobenzamide Chemical compound C1=C(OC)C(OC)=CC=C1NC(=O)C1=CC=CC=C1I IMDBISGKWOKHDY-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108700038288 rhodamine-phalloidin Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/205—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
- C07C43/2055—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring containing more than one ether bond
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a non-condensed ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Abstract
本发明提供了一种新型联苯衍生物化合物或其药学上可接受的盐。本发明的联苯衍生物化合物或其药学上可接受的盐是用于提高Nm23‑H1/NDPK活性的物质,并且可以抑制癌症的转移和成长,因此,不仅在预防、改善和治疗癌症方面,而且在抑制癌症转移方面均显示优异的效果。
Description
技术领域
本发明涉及一种新型联苯衍生物化合物及其用途,更特别地,涉及一种新型联苯衍生物化合物;一种用于治疗或预防癌症的药物组合物,其包含该新型联苯衍生物化合物或其药物学可接受的盐;一种治疗或预防癌症的方法,其包括施用药物组合物的步骤;一种用于抑制癌症转移的组合物,其包含该新型联苯衍生物化合物或其药物学可接受的盐;一种抑制癌症转移的方法,其包括施用药物组合物的步骤;一种用于预防或改善癌症的食品组合物,其包含该新型联苯衍生物化合物或其药物学可接受的盐,以及该联苯衍生物化合物或其药学上可接受的盐在制备用于治疗癌症的药物中的用途。
背景技术
癌症转移(肿瘤转移Tumor metastasis)是决定癌症患者预后的最重要因素之一,也是癌症相关死亡的一个主要原因。尽管已经做出许多努力以通过癌症治疗,包括手术、放射疗法和化学疗法的方法使患者存活,但是仍在努力提高癌症患者的生存率。癌症转移研究领域是克服癌症的最后策略之一,对癌症转移抑制剂(肿瘤转移抑制剂cancermetastasis suppressor)的研究对于开发抑制癌症转移的药物至关重要。
Nm23是编码参与正常组织的发育和分化的蛋白质的基因,并且已经报道了Nm23在各种转移性细胞系中表达降低。通常,由150至180个氨基酸组成的Nm23蛋白包含亮氨酸拉链基序(leucine zipper motif),并具有核苷二磷酸激酶(nucleoside diphosphatekinase,NDPK)活性。特别是已经发现Nm23-H1在癌症转移和其他各种细胞机制中起重要作用,例如细胞增殖、胚胎发育、分化和肿瘤形成。癌症转移通过多步骤的过程发生,其中原发肿瘤(primary tumor)组织中的癌细胞首先侵入血管,然后穿过血管,存活并在次级部位(secondary site)形成新的群落(colony)。已经发现Nm23,一种NDPK(核苷二磷酸激酶,nucleotide diphosphate kinase),是一种利用ATP将NDP(UDP、GDP和CDP)转换为NTP(UTP、GTP和CTP)的蛋白质,也是一种调节细胞内NTP水平的酶。另外,已经发现Nm23-H1的过表达与癌细胞侵袭的减少密切相关。例如,WO1997-035024公开了通过对癌细胞施用包括NDPK和核苷类似物的酶的组合来治疗癌症的方法。
基于该发现,研究已经朝着提高Nm23的表达或用细胞可透过(cell permeable)的Nm23-H1治疗的方向进行。具体地,已经证实了用MPA(Medroxyprogesterone acetate,乙酸甲羟孕酮)处理可以增加Nm23-H1的表达水平。该现象被认为是一种通过MPA治疗来抑制癌症转移的机制。然而,由于用MPA治疗除了提高Nm23-H1的水平以外还导致了意想不到的细胞内应答,因此MPA尚未被用作药物。
另外,近年来,已经提出了使用细胞可透过的Nm23-H1来抑制癌症转移的方法。细胞可透过的Nm23-H1以与可以穿过细胞膜的转运肽(transporter peptide)融合的形式引入细胞。结果,证实了用细胞可透过的Nm23-H1治疗显示出癌症转移抑制活性。然而,为了将这种细胞可透过的Nm23-H1用作蛋白质药物,其体内稳定性仍然是需要克服的挑战。另外,由于用于抑制癌症转移的药物在治疗时短时间内未显示出明显的效果,因此存在一个实际问题即不能选择昂贵的药物,例如蛋白质药物。
发明内容
技术问题
本发明人进行了广泛的研究并且付出巨大的努力,开发了能够更有效地抑制癌症发展和转移的药剂,结果发现使用新开发的联苯衍生物可以预防癌症的发展,治疗已发展的癌症并抑制已发展的癌症的转移,从而完成本发明。
技术方案
本发明的一个目的是提供一种新型联苯衍生物化合物。
本发明的另一个目的是提供一种用于治疗或预防癌症的药物组合物,该药物组合物包含新型联苯衍生物化合物或其药学上可接受的盐。
本发明的又一个目的是提供一种用于治疗或预防癌症的方法,该方法包括施用药物组合物的步骤。
本发明的又一个目的是提供一种用于抑制癌症转移的药物组合物,该药物组合物包含新型联苯衍生物化合物或其药学上可接受的盐。
本发明的又一个目的是提供一种用于抑制癌症转移的方法,该方法包括施用药物组合物的步骤。
本发明的进而又一个目的是提供一种用于预防或改善癌症的食品组合物,其包含新型联苯衍生物化合物或其药学上可接受的盐。
本发明的进而又一个目的是提供联苯衍生物化合物或其药学上可接受的盐在制备用于治疗癌症的药物中的用途。
有利效果
根据本发明的式1新型联苯衍生物化合物或其药学上可接受的盐是一种Nm23-H1/NDPK活性增强物质,可以抑制癌症转移和生长。因此,本发明的组合物不仅在预防、改善和治疗癌症方面,而且在抑制癌症转移方面均显示优异的效果。
附图简要说明
图1显示了评估在不同浓度下实施例1的化合物(B038)的NDPK活性增强效果的结果。
图2显示了评估实施例1(Exp.1)的化合物的侵袭抑制效果的结果。
图3显示了证实用实施例1的化合物治疗的癌症转移抑制的结果。
实施发明的最佳方式
为了实现上述目的,本发明的一个方面提供了下式1的新型联苯衍生物化合物或其药学上可接受的盐:
[式1]
其中,
R1至R4各自独立地为氢、羟基或C1至C3的烷氧基;其中C1至C3的烷氧基是选自甲氧基、乙氧基和丙氧基构成的组中的任一种。
优选地,式1化合物中的R1至R4各自独立地为羟基或甲氧基。更优选地,式1化合物中的R1至R4各自独立地为羟基或甲氧基且具有至少两个甲氧基。
另外,根据本发明的一个实施方式,式1化合物是选自以下化合物构成的组中的任一种:
如本文所用,术语“药学上可接受的盐”是指在药学领域中通常使用的盐。盐的实例包括:与钙、钾、钠、镁等形成的无机离子盐;与盐酸、硝酸、磷酸、溴酸、碘酸、高氯酸、硫酸等形成的无机酸盐;与乙酸、三氟乙酸、柠檬酸、马来酸、琥珀酸、草酸、苯甲酸、酒石酸、富马酸、扁桃酸、丙酸、乳酸、乙醇酸、葡萄糖酸、半乳糖醛酸、谷氨酸、戊二酸、葡萄糖醛酸、天冬氨酸、抗坏血酸、碳酸、香草酸、氢碘酸等形成的有机酸盐;与甲磺酸、乙磺酸、苯磺酸、对甲苯磺酸、萘磺酸等形成的磺酸盐;与甘氨酸、精氨酸、赖氨酸等形成的氨基酸盐;和与三甲胺、三乙胺、氨、吡啶、甲基吡啶等形成的胺盐。然而,在本发明中指的盐的类型不限于以上列出的盐。
本发明的另一方面提供了一种用于制备式1的联苯衍生物化合物的方法。
该联苯衍生物可以通过以下反应方案1、2或3所示的反应路线通过连续或会聚的合成路线来生产。
[反应方案1]
式1化合物是通过将溴化三苯基膦衍生物与2-溴苯甲醛反应,然后在氧化铂存在下与氢进行还原反应,之后与硼酸频哪醇酯衍生物、碳酸钾和四(三苯基膦)钯反应来合成。
因此,可以制备实施例5至11的化合物。
在上述反应方案1中,R各自独立地为氢或C1-C3烷基,优选氢或甲基。
[反应方案2]
在上述反应方案2中,实施例1的化合物可以通过在Pd/C的存在下与氢进行还原反应来合成。
另外,在上述反应方案2中,实施例2的化合物可以通过将NaHCO3水溶液添加至2-(3,4-二甲氧基苯乙烯基)-3'4'-二甲氧基联苯后进行反应来合成。
[反应方案3]
在上述反应方案3中,实施例3和4的化合物可以通过在把Pd催化剂和碳酸钾(3.0当量)加入二恶烷和蒸馏水中后,使上述硼酸衍生物与反应物反应来合成。
在上述反应方案3中,R1至R4如式1中所定义,且L2为-(NH-C(=O))-或-(C(=O)-NH)-。
根据本发明的一个实施方式,式1的联苯衍生物化合物可以根据反应方案中所示的顺序合成,但是也可以通过本文提出的方法或类似方法合成。因此,其合成路线不限于反应方案中所示的路线。起始原料是商业上可获得的,或者可以通过与下面所示的方法类似的方法来制备。
通过上述方法合成的联苯衍生物化合物或中间体的分离和纯化可以通过在制药领域中使用的任何合适的分离或纯化方法进行,例如过滤、萃取、结晶、柱色谱法、薄层色谱法、厚层色谱法、制备型低压或高压液相色谱法,或这些方法的组合。
本发明的又一方面提供了一种用于治疗或预防癌症的药物组合物,该药物组合物包含式1的联苯衍生物化合物或其药学上可接受的盐作为活性成分。
在本发明中,所述癌症没有特别限制,只要其可以通过根据本发明提供的式1的联苯衍生物化合物或其药学上可接受的盐治疗或预防即可。在一个示例中,癌症可以是乳腺癌、肺癌、黑素瘤、***癌、结肠直肠癌、膀胱癌、骨癌、血液癌、甲状腺癌、甲状旁腺癌、骨髓癌、直肠癌、咽喉癌(throat cancer)、喉癌(laryngeal cancer)、食道癌、胰腺癌、胃癌、舌癌、皮肤癌、脑瘤、子宫癌、头或颈癌、胆囊癌、口腔癌、结肠癌、***癌、中枢神经***肿瘤、肝癌、大肠癌等。在另一个示例中、癌症可以是乳腺癌、肺癌、结肠直肠癌、皮肤癌等。
根据本发明的一个实施方式,式1的联苯衍生物化合物或其药学上可接受的盐是一种增强Nm23-H1/NDPK活性的物质,并且可抑制癌症转移和生长。
因此,式1的联苯衍生物化合物或其药学上可接受的盐不仅在癌症的预防或治疗方面表现出效果,还在抑制癌症转移方面表现出效果。
如本文所用,术语“治疗”是指通过施用联苯衍生物化合物或其药学上可接受的盐来改善或有益地改变癌症症状的任何活动。
如本文所用,术语“预防”是指通过施用联苯衍生物化合物或其药学上可接受的盐来抑制或延缓癌症的任何活动。
本发明的药物组合物可以包括基于组合物的总重量的0.001至80wt%,具体地0.001至70wt%,更具体地0.001至60wt%的联苯衍生物化合物或其药学上可接受的盐,但不限于此。
对于给药,本发明的药物组合物除包含式1的联苯衍生物化合物或其药学上可接受的盐之外,可进一步包含至少一种药学上可接受的载体。作为药学上可接受的载体,可以使用盐水、无菌水、林格氏溶液、缓冲盐水、右旋糖溶液、麦芽糊精溶液、甘油、乙醇或其中两种或更多种的混合物。如果必要,药物组合物可以包含其他常规添加剂,例如抗氧化剂、缓冲剂和抑菌剂。另外,药物组合物可通过进一步添加稀释剂、分散剂、表面活性剂、粘合剂和润滑剂配制成可注射制剂,例如水溶液剂、悬浮剂或乳剂,或者是丸剂、胶囊剂、颗粒剂或片剂。因此,本发明的药物组合物可以是以贴剂、液体剂、丸剂、胶囊剂、颗粒剂、片剂、栓剂等形式。这些制剂可通过任何用于本领域的制剂的常规制备方法或在雷明顿药物科学(Remington's Pharmaceutical Science)(最新版),Mack出版公司,伊斯顿宾夕法尼亚州中公开的方法制备,并且可以根据每种病症或其成分以不同的形式制备。
本发明的药物组合物可以根据所需方法经口服或肠胃外(例如,静脉内,皮下,腹腔内或局部)施用,并且其施用剂量可以在很宽的范围内,这取决于患者的体重、年龄、性别、健康状况和饮食、给药持续时间、给药方式、***率和疾病的严重程度。本发明的式1化合物可以每天一次或几次,以约1至1000mg/kg,优选5至100mg/kg的日剂量施用。
本发明的药物组合物除了包含式1的联苯衍生物化合物或其药学上可接受的盐之外,可以进一步包含至少一种活性成分,其表现出的药物作用与式1的联苯衍生物化合物或其药学上可接受的盐的作用相同或相似。
本发明也提供了用于治疗或预防癌症的方法,该方法包括向有患癌风险或已患癌症的受试者施用用于治疗或预防癌症的联苯衍生物化合物、其药学上可接受的盐或药物组合物的步骤。
此处术语“联苯衍生物化合物”、“药学上可接受的盐”、“治疗”和“预防”如上定义。
如本文所用,术语“受试者”是指已患癌症或有患癌风险的所有动物,包括人类、大鼠、小鼠和家畜。在特定的示例中,受试者可以是包括人类的哺乳动物。
本发明的药物组合物以治疗有效量施用。术语“治疗有效量”是指足以以适用于任何医学治疗的合理的收益/风险比来治疗疾病的量。药物组合物的有效剂量水平可以根据以下因素确定,所述因素包括受试者的类型、疾病严重程度、年龄和性别、药物活性、对药物的敏感性、给药持续时间、给药途径、***率、治疗持续时间、与该组合物组合使用的药物、以及医学领域众所周知的其他因素。例如,联苯衍生物化合物或其药学上可接受的盐可以以日剂量为0.01至500mg/kg,具体地日剂量为10至100mg/kg施用,并且施用可以每天进行一次或多次。
本发明的治疗方法也包括通过施用式1的化合物,在症状发作之前抑制或避免疾病的症状以及解决疾病本身。在疾病或病症的管理中,特定活性成分的预防或治疗剂量可以根据疾病或病症的性质(nature)和严重性以及活性成分的施用途径而变化。剂量和剂量的施用频率也将根据年龄、体重和个体患者的反应而变化。考虑了这些因素,本领域技术人员可以容易地选择合适的剂量方案。另外,本发明的治疗方法可以进一步包括将治疗有效量的对治疗该疾病有帮助的另外的活性药剂与式1的化合物一起施用,其中所述另外的活性药剂可能表现出与式1的化合物协同或辅助作用。
本发明也提供了一种用于抑制癌症转移的药物组合物,该药物组合物包含作为活性成分的式1的联苯衍生物化合物或其药学上可接受的盐。本发明还提供了用于抑制癌症转移的方法,该方法包括将用于抑制癌症转移的组合物施用于有癌症转移风险或已癌症转移的受试者的步骤。
此处术语“联苯衍生物化合物”、“药学上可接受的盐”、“治疗”、“预防”和“受试者”如上所定义。
本发明的组合物显示出通过提高Nm23-H1/NDPK活性来抑制癌症转移的优异效果。
本发明还提供了一种用于预防或减轻癌症的食品组合物,该食品组合物包含作为活性成分的式1的联苯衍生物化合物或其药学上可接受的盐。
本发明的食物组合物可以作为健康功能性食品。术语“健康功能性食品”是指使用对人身体功能性有益的,且符合《健康功能性食品法》第6727号的规定的原料或成分制造和加工的食品。术语“功能性”是指食物的摄入旨在控制人体结构和功能上的营养或对健康产生有益的作用,例如生理作用。
本发明的食品组合物可以包含常规的食品添加剂。除非另有说明,否则食品添加剂的适用性应由符合韩国食品药品管理局批准的《韩国食品添加剂法典的一般规定和通用测试方法》的相关条款中的规范和标准确定。
出于预防和/或改善癌症的目的,本发明的食品组合物可以包含基于组合物的总重量的0.01至95wt%,优选1至80wt%的式1的化合物。另外,出于预防和/或改善癌症的目的,食品组合物可以以片剂、胶囊剂、粉剂、颗粒剂、液体剂、丸剂、饮料等形式制备和加工。
本发明还提供了式1的联苯衍生物化合物或其药学上可接受的盐在制备用于治疗癌症的药物中的用途。
用于制备药物的式1化合物可以与可接受的佐剂、稀释剂或载体等混合,并且可以与其他活性成分组合以形成在活性成分之间表现出协同作用的组合制剂。
除非它们彼此矛盾,否则在本发明的组合物、用途和治疗方法中提到的事项被等同地应用。
发明实施方式
下文中,将详细描述本发明的实施例,以使本领域技术人员可以容易地实施本发明。然而,本发明可以以各种不同的形式实施,并不限于在此描述的实施例。
在本发明的以下实施例中,除非另有说明,否则下文提到的试剂和溶剂均购自西格玛-奥德里奇(Sigma-Aldrich)、TCI,使用手性IB色谱柱(Hex/iPA=80/20,0.5mL/min)进行HPLC。使用硅胶60(230-400目ASTM)作为用于柱色谱的硅胶。使用布鲁克傅里叶变换AV300(300MHz)光谱仪,布鲁克傅里叶变换AV400(400MHz)光谱仪或安捷伦科技DD2(600MHz)检测1H NMR数据。
实施例1. 2-(3,4-二甲氧基苯乙基)-3',4'-二甲氧基-1,1'-联苯(HYL-NM-038)
的合成
邻溴苯甲醛(1.0当量)溶解在DMF中,然后将3,4-二甲氧基苯基硼酸(1.0当量)、2MNa2CO3水溶液(3.0当量)和Pd(PPh3)4(0.01当量)在室温下加入其中。混合物在80℃搅拌过夜,然后用乙酸乙酯稀释。接着向其中加入氯化铵水溶液和水终止反应。接下来,反应混合物用乙酸乙酯萃取,并将有机层用MgSO4干燥。过滤混合物,浓缩收集的有机层,然后在硅胶上使用柱色谱法纯化,从而合成目标化合物。
1H NMR(300MHz,CDCl3)δ9.98(s,1H),7.98(d,J=7.9Hz,1H),7.61(td,J=7.5,1.4Hz,1H),7.45(t,J=8.0Hz,2H),6.98-6.85(m,3H),3.93(s,3H),3.89(s,3H).
在0℃,将上述合成的化合物与n-BuLi(2.48M在正己烷中)(1.95当量)一起添加至苄基膦酸二烷基酯(2.0当量)的四氢呋喃溶液中。混合物在室温搅拌30分钟,然后冷却至0℃,并使用套管向其中加入顺式醛(1.0当量)和DMPU(5.0当量)的THF溶液。所得混合物在室温搅拌过夜,然后通过向其中加入氯化铵水溶液和水终止反应。反应混合物用乙酸乙酯萃取,用MgSO4干燥,浓缩,然后在硅胶上使用柱色谱法纯化。
1H NMR(599MHz,CDCl3)δ7.70(d,J=7.6Hz,1H),7.33(d,J=7.1Hz,2H),7.30(d,J=6.2Hz,1H),7.03-6.91(m,6H),6.89(d,J=1.6Hz,1H),6.80(d,J=8.3Hz,1H),3.92(s,3H),3.86(s,3H),3.84(s,3H),3.83(s,3H).
将上述合成的化合物溶解在甲醇和二氯甲烷的1:1溶剂中。向其中添加Pd/C(10wt%)(0.1当量)后,将混合物在氢气气氛下搅拌3小时。之后,将搅拌的混合物通过硅藻土和二氧化硅过滤,将有机溶剂蒸发掉,然后将浓缩的有机化合物在硅胶上使用柱色谱法纯化,得到所需的产物[2-(3,4-二甲氧基苯乙基)-3',4'-二甲氧基-1,1'-联苯]。
1H NMR(300MHz,氯仿-d)δ7.31-7.25(m,2H),7.24-7.17(m,2H),6.89(d,J=8.6Hz,1H),6.79(dt,J=4.3,2.2Hz,2H),6.68(d,J=8.1Hz,1H),6.49(dd,J=8.1,2.0Hz,1H),6.35(d,J=2.0Hz,1H),3.91(s,3H),3.84(s,3H),3.81(s,3H),3.73(s,3H),2.95-2.81(m,2H),2.73-2.60(m,2H).
实施例2. 2-(3',4'--二甲氧基-[1,1'-联苯]-2-基)-3-(3,4-二甲氧基苯基)环
氧乙烷(HYL-NM-039)的合成
将NaHCO3水溶液添加至2-(3,4-二甲氧基苯乙烯基)-3'4'-二甲氧基联苯(1.0当量)的丙酮和乙腈溶液中,并冷却至0℃的温度。向其中加入过氧单磺酸钾(2.2当量),然后搅拌4小时。向其中加入蒸馏水终止反应,然后将反应混合物用乙酸乙酯萃取,用MgSO4干燥,然后浓缩。所得混合物使用柱色谱法在硅胶上纯化。得到所需产物[2-(3',4'-二甲氧基-[1,1'-联苯]-2-基)-3-(3,4-二甲氧基苯基)环氧乙烷]。
1H NMR(300MHz,苯-d6)δ7.84-7.76(m,1H),7.50-7.37(m,3H),7.27(dd,J=7.1,2.1Hz,2H),7.07-6.85(m,4H),6.61(d,J=8.2Hz,1H),6.50(d,J=8.2Hz,1H),3.40(s,3H),3.36(d,J=1.1Hz,6H),3.33(s,3H).
实施例3.N-(3,4-二甲氧基苯基)-3',4'二甲氧基-[1,1'-联苯基]-2-甲酰胺
(HYL-NM-041)的合成
在0℃下,将2ml DMF添加到2-碘苯甲酸(1.0当量)的二氯甲烷溶液中。然后,向其中滴加草酰氯(2.0当量),然后搅拌1小时。接下来,将3,4-二甲氧基苯胺加入到混合物中,然后将其温热至室温并搅拌2个半小时。反应混合物用二氯甲烷稀释,然后向其中加入水终止反应。混合物用二氯甲烷萃取,用MgSO4干燥,然后在真空下浓缩。接下来,使用柱色谱法在硅胶上纯化浓缩物,得到所需产物。
在室温下,将四(三苯基膦)钯(0.01当量)和K2CO3(3.0当量)加入到N-(3,4-二甲氧基苯基)-2-碘代苯甲酰胺(1.0当量)和3,4-二甲氧基苯基硼酸(2.0当量)的DMF(1ml)和蒸馏水(0.1ml)溶液中。然后,将混合物在110℃下搅拌16小时。接下来,向其中加入氯化铵水溶液来终止反应,然后反应混合物用乙酸乙酯萃取,MgSO4干燥,然后在真空下浓缩。然后,将浓缩物在硅胶上使用柱色谱法纯化,得到所需产物[N-(3,4-二甲氧基苯基)-3',4'-二甲氧基-[1,1'-联苯基]-2-甲酰胺]。
1H NMR(300MHz,氯仿-d)δ8.02(s,1H),7.88(dd,J=7.5,1.6Hz,1H),7.61-7.40(m,3H),7.07(dd,J=8.2,2.1Hz,1H),7.03-6.93(m,4H),6.73(d,J=8.6Hz,1H),6.52(dd,J=8.6,2.5Hz,1H),3.93(s,3H),3.84(d,J=2.2Hz,6H),3.81(s,3H),2.97(s,1H),2.90(s,1H).
实施例4.N-(3',4'-二甲氧基-[1,1'-联苯]-2-基)-3,4-二甲氧基苯甲酰胺(HYL-
NM-042)的合成
在0℃,向3,4-二甲氧基苯甲酸(1.0当量)的二氯甲烷溶液中,以二氯甲烷的1/10的量加入DMF。向其中滴加草酰氯(2.0当量),然后搅拌1小时。将混合物温热至室温,然后进一步搅拌30分钟。之后,向其中加入2-碘苯胺(5.0当量),然后进一步搅拌2小时。将5mL的四氢呋喃继续加入到混合物中,随后进一步搅拌30分钟,然后向其中加入蒸馏水终止反应。将混合物用二氯甲烷萃取,用MgSO4干燥,然后在真空下浓缩。使用柱色谱法在硅胶上纯化浓缩物,得到所需产物。
1H NMR(300MHz,氯仿-d)δ8.41(dd,J=8.3,1.6Hz,1H),8.23(s,1H),7.78(dd,J=8.0,1.5Hz,1H),7.61-7.44(m,2H),7.36(ddd,J=8.6,7.4,1.5Hz,1H),6.93(d,J=8.2Hz,1H),6.88-6.79(m,1H),3.94(s,4H),3.93(s,3H).
将N-(2-碘苯基)-3,4-二甲氧基苯甲酰胺(1.0当量),3,4-二甲氧基硼酸(2.0当量),Pd催化剂(0.01当量)和碳酸钾(3.0当量)溶于二恶烷和蒸馏水(10:1)中。将混合物在100℃搅拌13小时,然后向其中加入氯化铵水溶液终止反应。有机混合物用乙酸乙酯萃取,用MgSO4干燥,然后在真空下浓缩。然后,使用柱色谱法在硅胶上纯化浓缩物,得到所需产物[N-(3',4'-二甲氧基-[1,1'-联苯]-2-基)-3,4-二甲氧基苯甲酰胺]。
1H NMR(300MHz,氯仿-d)δ8.50(dd,J=8.1,1.2Hz,1H),8.04(s,1H),7.39(ddd,J=8.3,7.2,1.7Hz,1H),7.32-7.22(m,2H),7.16(td,J=7.5,1.3Hz,1H),7.06-6.95(m,3H),6.94-6.88(m,1H),6.78(d,J=8.4Hz,1H),3.92(s,3H),3.87(s,3H),3.84(s,3H),3.81(s,3H).
实施例5至11.化合物(HYL-NM-049至055)的合成
通用步骤A
在0℃下,将溴化三苯基膦衍生物(1.2当量)加入到四氢呋喃中,然后向其中加入t-BuOK(1.4当量)。30分钟后,在10分钟内将2-溴苯甲醛(1.0当量)的四氢呋喃溶液加入到该混合物中。反应混合物温热至室温,然后搅拌16小时。然后,向其中加入蒸馏水终止反应,并将反应混合物用乙酸乙酯萃取。萃取液用MgSO4干燥,浓缩,然后在硅胶上使用柱色谱法纯化,得到所需产物。
将合成的溴化物(1当量)溶解在二氯甲烷中,然后在氢气气氛下向其中加入氧化铂(0.73当量)。混合物搅拌6小时,通过二氧化硅和硅藻土过滤,然后在真空下浓缩。使用柱色谱法在硅胶上纯化浓缩物,得到所需产物。
通用步骤B
将硼烷频哪醇酯衍生物(1.5当量),碳酸钾(3.0当量)和四(三苯基膦)钯(0.05当量)溶解在DME/蒸馏水(2/1)中。使用套管向该混合物中缓慢滴加溴化物(1.0当量)的DME溶液。将混合物在90℃混合直至起始原料完全消失。反应完成后,将反应混合物冷却至室温,然后向混合物中加入蒸馏水终止反应。反应混合物用乙酸乙酯萃取,用盐水洗涤。有机混合物用MgSO4干燥,浓缩,然后在硅胶上使用柱色谱法纯化,得到所需产物。
通用步骤C(通用步骤A的反应物的合成步骤)
将苄醇衍生物(1.0当量)和三苯基膦溴化氢(1.0当量)在乙腈中的溶液在85℃下搅拌2小时。当产物作为盐合成出来时,将其冷却至室温,然后过滤。用乙腈洗涤产物。
利用每个位置上的R正确地被H或Me取代的反应物,根据通用步骤A,B和C合成以下七个化合物。
实施例5. 2'-(3,4-二甲氧基苯乙基)-3-甲氧基-[1,1'-联苯]-4-醇
1H NMR(400MHz,氯仿-d)δ7.25(d,J=2.5Hz,1H),7.24-7.15(m,2H),6.86(dd,J=5.0,3.1Hz,2H),6.77-6.65(m,2H),6.53(dd,J=8.1,1.9Hz,1H),6.40(d,J=2.0Hz,1H),3.91(s,3H),3.81(d,J=1.1Hz,3H),3.74(s,3H),2.93-2.82(m,2H),2.71-2.61(m,2H).
实施例6. 2'-(3,4-二甲氧基苯乙基)-4-甲氧基-[1,1'-联苯]-3-醇
1H NMR(400MHz,氯仿-d)δ7.35-7.25(m,2H),7.22-7.15(m,2H),6.89-6.81(m,2H),6.75-6.65(m,2H),6.53(dd,J=8.1,2.0Hz,1H),6.40(d,J=2.0Hz,1H),5.63(s,1H),3.91(s,3H),3.81(s,3H),3.74(s,3H),2.92-2.82(m,2H),2.69-2.59(m,2H).
实施例7. 5-(2-(3',4'-二甲氧基-[1,1'-联苯]-2-基)乙基)-2-甲氧基苯酚
在通用步骤B中,使用硼酸代替频哪醇硼酸酯。用作溶剂的DME和H2O之间的比例从2:1更改为5:1。
1H NMR(400MHz,氯仿-d)δ7.29-7.25(m,2H),7.23-7.18(m,1H),6.90(d,J=8.1Hz,1H),6.85-6.77(m,2H),6.69(dd,J=15.1,8.4Hz,1H),6.57(d,J=2.1Hz,1H),6.51-6.39(m,1H),3.92(s,3H),3.84(s,3H),3.82(s,3H),2.96-2.73(m,2H),2.69-2.54(m,2H).
实施例8. 2'-(3-羟基-4-甲氧基苯乙基)-3-甲氧基-[1,1'-联苯]-4-醇
1H NMR(400MHz,氯仿-d)δ7.29-7.23(m,2H),7.22-7.16(m,2H),6.90-6.83(m,2H),6.76(dd,J=8.2,2.1Hz,1H),6.68(d,J=8.1Hz,1H),6.58(d,J=2.1Hz,1H),6.48(dd,J=8.2,2.1Hz,1H),5.65(s,1H),5.52(s,1H),3.93(s,3H),3.82(s,3H),2.92-2.78(m,2H),2.72-2.57(m,2H).
实施例9. 2'-(3-羟基-4-甲氧基苯乙基)-4-甲氧基-[1,1'-联苯]-3-醇
1H NMR(400MHz,氯仿-d)δ7.27-7.24(m,2H),7.23-7.15(m,2H),6.91-6.84(m,2H),6.76(dd,J=8.2,2.1Hz,1H),6.68(d,J=8.2Hz,1H),6.58(d,J=2.1Hz,1H),6.48(dd,J=8.2,2.1Hz,1H),5.65(s,1H),5.52(s,1H),3.92(s,3H),3.82(s,3H),2.96-2.74(m,2H),2.74-2.58(m,2H).
实施例10. 4-(2-(3',4'-二甲氧基-[1,1'-联苯]-2-基)乙基)-2-甲氧基苯酚
在通用步骤B中,使用硼酸代替频哪醇硼酸酯。用作溶剂的DME和H2O之间的比例从2:1更改为5:1。
1H NMR(400MHz,氯仿-d)δ7.36-7.25(m,2H),7.24-7.14(m,2H),6.93-6.85(m,1H),6.82-6.75(m,2H),6.72(d,J=8.0Hz,1H),6.44(dd,J=8.0,1.9Hz,1H),6.31(d,J=1.9Hz,1H),5.40(s,1H),3.90(s,3H),3.84(s,3H),3.73(s,3H),2.90-2.79(m,2H),2.70-2.55(m,2H).
实施例11. 2'-(4-羟基-3-甲氧基苯乙基)-3-甲氧基-[1,1'-联苯]-4-醇
1H NMR(400MHz,氯仿-d)δ7.26-7.24(m,2H),7.23-7.13(m,2H),6.89-6.82(m,2H),6.78-6.62(m,2H),6.48(dd,J=8.0,2.0Hz,1H),6.38(d,J=1.9Hz,1H),5.66(s,1H),5.44(s,1H),3.91(s,3H),3.75(s,3H),2.91-2.79(m,2H),2.71-2.57(m,2H).
实施例1至11合成的本发明化合物的结构总结于下表1中。
[表1]
实施例12.验证增强的NDPK活性
在室温条件下,将5ng重组Nm23-H1与每种测试化合物(实施例1至3)在NDPK测定缓冲液(20mM HEPES,3mM MgCl2)中孵育10分钟,然后与5μM ADP反应1分钟来进行NDPK测定。
通过基于细胞的NDPK测定确认了相同的效果,基于细胞的NDPK测定如下进行:用蛋白酶抑制剂混合物(protease inhibitor cocktail)和NDPK测定缓冲液(NDPK assaybuffer)裂解5,000K MDA-MB-231细胞,并将得到的细胞裂解液在4℃以8,000rpm离心10分钟。将40μL的裂解物与每种测试化合物孵育5分钟,然后向其中加入50μM UDP,然后与NDPK反应。通过ATP测定试剂盒(分子探针,美国)评估ATP的消耗量。
结果显示在下表2中。
[表2]
实施例化合物 | NDPK活性 |
1 | 6.55 |
2 | 4.08 |
3 | 1.32 |
4 | 1.52 |
5 | 4 |
6 | 1.9 |
7 | 3.5 |
10 | 2.6 |
如上所述,证实了实施例化合物表现出增强NDPK活性(增强Nm23-H1活性)的优异效果。
实施例13.在不同浓度下验证实施例1的化合物的NDPK活性增强效果
以与实施例2相同的方式评估不同浓度的实施例1的化合物的NDPK活性增强效果,结果如图1所示。
如图1所示,证实了即使在低浓度下用实施例1的化合物处理也显示出增强NDPK活性的优异效果。
实施例14.通过基质胶侵袭试验验证癌症转移抑制
具有带有或没有基质胶涂层的聚碳酸酯膜(孔径:8μm)的单元盒(康宁,美国)进行侵袭测定。膜上涂有50μg MatrigelTM-基的膜基质(BD生物科学,美国)。将5×104个MDA-MB-231细胞与实施例1的化合物一起接种到无血清培养基中的上腔室中,并在下腔室中填充含有10%FBS的培养基。在37℃下孵育24小时后,将膜上侧的细胞移出。用在25%甲醇中的0.5%结晶紫将侵袭到膜下侧的细胞染色,并在显微镜下放大100倍计数。
结果如图2所示。
图2(A)显示了显微镜照片,图2(B)显示了对侵袭细胞进行计数的结果。如图2所示,证实了用实施例1的化合物处理显著抑制了细胞侵袭。
实施例15.通过免疫荧光染色测定验证癌症转移抑制
MDA-MB-231细胞在SecureslipTM(西格玛)细胞培养玻璃盖玻片上生长至50-70%的汇合度,然后使用或不用实施例1的化合物(B038)处理多次。用冷的HBSS轻轻清洗细胞,然后在室温下用RBS中含4%多聚甲醛的HBSS固定10分钟。用HBSS洗涤后,在室温下用0.1%曲拉通X-100(Triton-X)透化10分钟。在用HBSS洗涤两次后,在室温下用HBSS中的3%BSA,0.2%吐温20和0.2%明胶封闭细胞1小时,并在37℃下用一抗孵育2小时。F-肌动蛋白用罗丹明-鬼笔环肽(赛默飞科技)在37℃染色2小时,然后用HBSS洗涤3次,20分钟。用抗褪色溶液(anti-fading solution)处理盖玻片(Cover slips),并使用LSM510 META(蔡司)激光扫描共聚焦显微镜的x63物镜观察。
结果如图3所示。
如图3所示,从F-肌动蛋白在MDA-MB-231细胞中的定位可以确认褶皱(Ruffle)减少并且细胞间接触增加(B038)。这表明实施例1的化合物通过抑制参与通过Nm23-H1进行细胞迁移的Rac1的活性以及减少细胞迁移抑制癌细胞转移。
综合以上结果,本发明的新型联苯衍生物化合物通过增强NDPK活性来抑制癌症转移。即,本发明的新型化合物可以表现出优异的抑制癌症转移的效果,因此可以用作表现出优异的预防和治疗效果的抗癌剂和抗癌佐剂。
尽管已经参考特定特征详细描述了本发明,但是对于本领域技术人员显而易见的是,这种详细的描述仅是其优选实施方式,并且不限制本发明的范围。因此,本发明的实质范围将由所附权利要求及其等同物限定。
Claims (6)
2.一种用于治疗或预防癌症的药物组合物,所述药物组合物包含根据权利要求1所述的联苯衍生物化合物作为活性成分。
3.根据权利要求2所述的药物组合物,其特征在于,所述癌症是选自下组的癌症:乳腺癌、肺癌、黑素瘤、***癌、膀胱癌、骨癌、血液癌、甲状腺癌、甲状旁腺癌、骨髓癌、直肠癌、咽喉癌、喉癌、食道癌、胰腺癌、胃癌、舌癌、皮肤癌、脑癌、子宫癌、头或颈癌、胆囊癌、口腔癌、结肠癌、***癌、中枢神经***肿瘤、肝癌、大肠癌及其组合。
4.根据权利要求2所述的药物组合物,其特征在于,所述癌症是选自下组的癌症:乳腺癌、肺癌、结肠直肠癌和皮肤癌。
5.一种用于抑制癌症转移的组合物,所述组合物包含根据权利要求1所述的联苯衍生物化合物作为活性成分。
6.一种用于预防或减轻癌症的食品组合物,所述食品组合物包含根据权利要求1所述的联苯衍生物化合物作为活性成分。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0062122 | 2018-05-30 | ||
KR1020180062122A KR102303140B1 (ko) | 2018-05-30 | 2018-05-30 | 신규 바이페닐 유도체 화합물 및 이의 용도 |
PCT/KR2019/006519 WO2019231262A1 (ko) | 2018-05-30 | 2019-05-30 | 신규 바이페닐 유도체 화합물 및 이의 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112512999A CN112512999A (zh) | 2021-03-16 |
CN112512999B true CN112512999B (zh) | 2023-06-13 |
Family
ID=68698379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980050493.0A Active CN112512999B (zh) | 2018-05-30 | 2019-05-30 | 新型联苯衍生物化合物及其用途 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11939308B2 (zh) |
EP (1) | EP3805192A4 (zh) |
KR (1) | KR102303140B1 (zh) |
CN (1) | CN112512999B (zh) |
WO (1) | WO2019231262A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102442998B1 (ko) * | 2019-12-20 | 2022-09-14 | 주식회사 하임네이처 | NDPK 활성제 및 H-prune 억제제를 포함하는 암의 예방 또는 치료용 약학 조성물 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103980153A (zh) * | 2014-05-30 | 2014-08-13 | 西安交通大学 | 具有抗肿瘤活性的联苯酰胺化合物及其制备方法和应用 |
WO2014170706A1 (en) * | 2013-04-15 | 2014-10-23 | Università Degli Studi Di Bari | Galloyl benzamide-based compounds as jnk modulators |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2746016B1 (fr) | 1996-03-15 | 1998-04-17 | Combinaisons d'enzymes pour la destruction de cellules proliferatives | |
US6780883B2 (en) | 1998-11-05 | 2004-08-24 | Warner-Lambert Company | Amide inhibitors of microsomal triglyceride transfer protein |
WO2014001363A1 (en) | 2012-06-25 | 2014-01-03 | Clevexel Pharma | Novel tetrazole derivatives and their use as potassium channel modulators |
KR102264110B1 (ko) * | 2018-05-30 | 2021-06-11 | 이화여자대학교 산학협력단 | 신규 바이페닐 유도체 화합물 및 이의 용도 |
-
2018
- 2018-05-30 KR KR1020180062122A patent/KR102303140B1/ko active IP Right Grant
-
2019
- 2019-05-30 CN CN201980050493.0A patent/CN112512999B/zh active Active
- 2019-05-30 WO PCT/KR2019/006519 patent/WO2019231262A1/ko unknown
- 2019-05-30 US US17/059,754 patent/US11939308B2/en active Active
- 2019-05-30 EP EP19811353.2A patent/EP3805192A4/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014170706A1 (en) * | 2013-04-15 | 2014-10-23 | Università Degli Studi Di Bari | Galloyl benzamide-based compounds as jnk modulators |
CN103980153A (zh) * | 2014-05-30 | 2014-08-13 | 西安交通大学 | 具有抗肿瘤活性的联苯酰胺化合物及其制备方法和应用 |
Non-Patent Citations (6)
Title |
---|
142. Some heterocyclic N-oxides;Mamalis, P., & Petrow, V.;《Journal of the Chemical Society》;19500101;第1950卷(第1期);表1 * |
Activation of AntimetastaticNm23-H1Gene Expression by Estrogen and Its α-Receptor;KWANG-HUEI LIN等;《Endocrinology》;20020201;第143卷(第2期);第467–475页 * |
Cobalt-Catalyzed C-H Arylations with Weakly-Coordinating Amides and Tetrazoles: Expedient Route to Angiotensin-II-Receptor Blockers;Jie Li等;《Chemistry-A European Journal》;20150407;第21卷(第15期);Scheme3 * |
Dibenzothiophenes and related compounds. IV. Reactions of 5-substituted 10,11-dihydrodibenzo(b,f)thiepinium salts with aryllithiums;HORI, M.等;《CHEMICAL & PHARMACEUTICAL BULLETIN》;19740925;第22卷(第9期);第2016页 * |
Efficient Synthesis of Phenanthridines Using Hendrickson Reagent Initiated Cascade Reaction under Mild Conditions;Jie Xi等;《Synlett.》;20100610;第11卷;第1677页表2 * |
Synthesis of Phenanthrenes by Cationic Chromium(III) Porphyrin-Catalyzed Dehydration Cycloaromatization;Wakabayashi Ryota等;《Synlett.》;20130923;第24卷(第17期);第2298页表2 * |
Also Published As
Publication number | Publication date |
---|---|
KR102303140B1 (ko) | 2021-09-16 |
US11939308B2 (en) | 2024-03-26 |
KR20190136425A (ko) | 2019-12-10 |
EP3805192A4 (en) | 2022-03-09 |
CN112512999A (zh) | 2021-03-16 |
WO2019231262A1 (ko) | 2019-12-05 |
EP3805192A1 (en) | 2021-04-14 |
US20210214324A1 (en) | 2021-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109952300B (zh) | 5或8-取代的咪唑并[1,5-a]吡啶 | |
KR101568724B1 (ko) | 신규한 화합물, 이의 생산 방법, 및 히스톤 디메틸라제 저해제로서 이의 용도 | |
TW201728579A (zh) | 作為檢測點激酶1 (chk1)抑制劑之3,5-二取代吡唑及其製備及應用 | |
WO2018184585A1 (zh) | 一种能抑制ido的化合物、其制备方法及其用途 | |
WO2018171688A1 (en) | Atf3 induction compounds | |
WO2012000421A1 (zh) | 棉酚衍生物在制备抗肿瘤药物中的应用 | |
CN112512999B (zh) | 新型联苯衍生物化合物及其用途 | |
CN107011238B (zh) | 一类组蛋白去乙酰化酶抑制剂及其制备方法和用途 | |
CN112513000B (zh) | 新型联苯衍生物化合物及其用途 | |
CN107151236A (zh) | 一种2,3-环氧丁二酰衍生物及其制备方法和用途 | |
KR20200041336A (ko) | 지방성 간 질환의 치료제 및 비만증의 치료제 | |
WO2011131102A1 (zh) | 含笑内酯的制备方法及其用途 | |
CN107200716B (zh) | 苯并噁嗪类化合物及其制备方法与应用 | |
KR102145416B1 (ko) | 베르베논 유도체를 포함하는 암 치료 또는 예방용 조성물 | |
WO2014169697A1 (zh) | 长春碱类衍生物及其制备方法和应用 | |
US9682954B2 (en) | Phenanthridine derivatives, preparation methods and uses thereof | |
CN109091472B (zh) | 含α,β不饱和酮的查尔酮类似物在制备抗肺癌药物中的应用 | |
KR20050085474A (ko) | 3-페닐-신놀린 동족체와 그것을 사용한 항종양제 | |
CN110963906B (zh) | 针对Fyn-CD147信号通路靶点的抗肿瘤化合物及其制备方法和应用 | |
JP7201181B2 (ja) | ペプチド系抗腫瘍薬の創製 | |
CN108186630B (zh) | 靛红类似物在制备抗肿瘤药物中的应用 | |
CN109705057B (zh) | 组蛋白去乙酰化酶抑制剂及其制备方法与用途 | |
EP3027591B1 (en) | Novel derivatives of a 3,4-dihydroisoquinoline-3-carboxylic acid having anti-cancer properties, a method for their synthesis, pharmaceutical compositions comprising said derivatives, and their use | |
KR101713027B1 (ko) | 페닐옥사졸계 유도체를 포함하는 암 예방 또는 치료용 조성물 | |
CN116768902A (zh) | 一种取代酚羟基苯基吡咯并嘧啶化合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: Special city, Seoul, Korea Patentee after: EWHA University INDUSTRY COLLABORATION FOUNDATION Address before: Special city, Seoul, Korea Patentee before: Ewha Women's University Industry University Cooperation |